Pioneering the Science
Pioneering the Science of Possibilities
Xequel Bio is a clinical stage biopharmaceutical company transforming its proprietary alpha-connexin carboxyl-terminal 1 (aCT1) peptide technology platform to develop drugs that will revolutionize the way the body responds to injury.
Led by a proven leadership team, Xequel Bio is poised for its next chapter of success leveraging deep R&D expertise and building on a proprietary platform with robust commercial potential.
This is our Xequel.
Pioneering the Science of Leadership
“At Xequel, we combine the power of leadership with our personal conviction to pioneer meaningful science that ultimately impacts doctors and patients.”
– Jerry St. Peter, CEO & Board Director
Pioneering the Science of Innovation
Xequel Bio’s alpha-connexin carboxyl-terminal 1 (aCT1) is a new chemical entity that restores gap junction integrity, enables intercellular communication, and regulates inflammation at the injury site, culminating in a healthy injury response. aCT1 is an unprecedented solution that promotes healing by rebuilding healthy tissue through accelerated re-epithelialization.
Pioneering the Science of Technology
Our proprietary aCT1 technology platform has extensive preclinical and clinical research to support multiple unique applications and formulations in Dermatology, Ophthalmology, and Pulmonology.
Pioneering the Science for Patients
We are committed to developing treatments that address unmet medical needs and revolutionize the way the body responds to injury.
Granexin® Gel is a topical formulation of aCT1 developed to address unmet clinical needs within the field of dermatology and wound healing.
iNexin™ Eye Drops
iNexin™ Eye Drops is an innovative formulation of aCT1 developed to address unmet needs within the field of ophthalmology focusing on corneal and retinal diseases.
aCT1 Inhalation Solution
aCT1 inhalation solution is a preclinical formulation being developed to address unmet needs within the field of pulmonology focusing on acute injury.
Xequel Bio To Present Corporate Overview and Clinical Trial Data at Eyecelerator® at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting
– Presentation Will Highlight Positive Clinical Trial Data on iNexin™ for Treatment of Corneal Injury – – Xequel Launches New
Xequel Bio Expands Leadership Team With Appointments Of Dr. Michael J. Brubaker As Chief Scientific Officer And Tony C. Tipton As Chief Operating Officer
Seasoned Biopharma Executives Bring Significant Clinical Development and Commercial Expertise Charleston, SC and Fort Worth, TX, July 26, 2022 –
Xequel Bio Announces Positive Results From Phase 1b Study Of INexinTM, A Novel ACT1 Ophthalmic Solution
Excellent Safety and Tolerability Profile for iNexin™ for the Treatment of Corneal Injury Early Efficacy Signals Provide Rationale to Advance